top of page
  • Writer's pictureKeith Ward

Kuria announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

- Kuria team to present potency, selectivity, and positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and retina disease


Kuria Therapeutics, a pharmaceutical company developing a platform of novel Nrf2 activators for ophthalmic disease, will be presenting three scientific posters at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024, a key ophthalmology conference which will be held from May 5 to May 9, 2024 in Seattle, WA.


Poster: SCO-116 exhibits potent, selective activation of NRF2 suitable for use in treatment of ocular diseases

Date: May 5, 2024

Presenter: Ralph Henry, PhD, Chief Technical Officer, Kuria


Poster: SCO-116 protects retinal pigment epithelium from oxidative insult in vitro and preserves visual function and retinal structure in sodium iodate-induced geographic atrophy in rats in vivo

Date: May 6, 2024

Presenter: Brooks Gentry, MD, Chief Medical Officer, Kuria 


Poster: SCO-116, a novel small-molecule NRF2 activator, potently induces NQO1 in multiple rabbit ocular tissues

Date: May 7, 2024

Presenter: Misty Stevens, PhD, Chief Operating Officer, Kuria 


Downloadable versions of these posters will be available on Kuria's website following their presentation at the ARVO meeting.


The ARVO Annual Meeting is the premier international scientific conference for vision research, and showcases the latest advances and innovation in ophthalmology. In addition to the poster presentations, Kuria's team will be available on-site in Seattle for one-on-one meetings during the event.


About Kuria Therapeutics, Inc.:

Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit www.kuriatx.com.

Recent Posts

See All

Comentarios


bottom of page